ClinicalTrials.gg
CompletedNCT05034484RUBY-1Updated May 9, 2023

A Study of ALPN-303 in Adult Healthy Volunteers

A Phase 1 interventional study of ALPN-303 and Placebo in Healthy Volunteers, sponsored by Alpine Immune Sciences, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Alpine Immune Sciences, Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteer
  • BAFF
  • APRIL
03

In context

Lead sponsor

Alpine Immune Sciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before Alpine Immune Sciences, Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Summary of Inclusion Criteria:

  • Able and willing to provide written
  • 18 to 32 kg/m2
  • Agree to avoid strenuous physical activity for 2 days prior to each study visit
  • Agree to use highly effective during the study (all participants) and for 90 days after study drug dosing (males) or for 60 days after study drug dosing (females)
  • Male participants must refrain from donating sperm during the study and for 90 days after study drug dosing
  • Female participants must not be pregnant or breastfeeding and must refrain from donating ova during the study and for 60 days after study drug dosing
  • Must have completed vaccination against SARS-CoV-2 at least 4 weeks prior to study drug dosing

Summary of Exclusion Criteria:

  • Any current disease, condition, or treatment that could interfere with the study, interfere with interpretation of the data, or pose an unacceptable risk to the participant
  • History or symptoms of significant psychiatric disease; mild, resolved depression or anxiety is acceptable
  • History of immunological disorders, auto-immune disorders, acquired or congenital immune deficiency; see protocol for clarifications/exceptions
  • History of significant hepatic or renal disease or impairment
  • Evidence of an active or suspected cancer or a history of within the previous 3 years; see protocol for exceptions
  • History of major organ transplantation with an existing functional graft
  • Use or receipt of prescription medications, over-the-counter medications, herbal remedies, or investigation products (study drugs) within protocol-defined timeframes prior to study entry; hormone replacement therapy initiated at least 2 months prior to Screening is acceptable
  • Significant loss of blood or blood product (including donation) over 500 mL or transfusion of any blood product during Screening or within 3 months of Screening
  • Unwilling to refrain from alcohol use ≥ 48 hours prior to Study Day -1.
  • Known , allergy, or intolerance to ALPN-303, Fc-based biologic therapy, or any of the contained in the ALPN-303 formulation
  • Immunization with any within 6 weeks prior to study drug administration, or expected to require any live vaccines during the study or within 6 weeks after receiving study drug
  • Acceptable laboratory assessments at Screening and Day -1
  • Positive screen for drugs of abuse or alcohol at Screening or Day -1
  • Positive tests for infectious disease (, , , SARS-CoV-2)
  • Acute infection during or within 4 weeks prior to Screening
  • History of frequent or atypical infections as defined per protocol; signs or symptoms of immunodeficiency
  • History or presence of any chronic infectious condition
  • Cardiac risk factors, as defined per protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    ALPN-303 Regimen A

    Drug: ALPN-303

  • Placebo comparator
    Placebo Regimen A

    Drug: Placebo

  • Experimental
    ALPN-303 Regimen B

    Drug: ALPN-303

  • Placebo comparator
    Placebo Regimen B

    Drug: Placebo

Interventions

  • Multiple dose levels will be evaluated.

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Treatment-emergent Adverse Events (TEAE)

    Type, incidence, and severity of TEAE as assessed by CTCAE

    Time frame: Day 1 through Day 30

07

Study locations

2 sites
  • Investigative Site
    Brisbane, Queensland 4006, Australia
  • Investigative Site
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2023, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Sep 5, 2021
StartActual
Nov 15, 2021
Primary completionActual
Feb 27, 2023
CompletionActual
Feb 27, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05034484
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Nov 15, 2021
Primary completion
Feb 27, 2023
Completion
Feb 27, 2023
Last update
May 9, 2023

Study contacts

Stanford Peng, MD PhD
study director · Alpine Immune Sciences, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion